Cite
HARVARD Citation
Ludwig, H. et al. (2017). Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Leukemia & lymphoma. 58 (10), pp. 2501-2504. [Online].